Popular Articles

Innovative Treatment Approach Offers New Hope For Eczema Sufferers With Moderate To Severe Disease PROTOPIC Ointment Can Help Prevent Eczema Flares
Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong flare-free intervals. PROTOPIC ointment (tacrolimus monohydrate) is already licensed to treat moderate and severe eczema (atopic dermatitis), often involving the treatment of flares as and when they occur.* It is now also approved for twice-weekly application to previously affected skin to prevent these exacerbations and prolong flare-free periods in PROTOPIC-responsive patients.ò€  Clinical studies have shown that this new approach brings significant benefits with over 40% of patients with moderate to severe eczema remaining flare-free for at least a year.1 Flares are known to place an enormous burden on patients. The International Study of Life with Atopic Eczema (ISOLATE) found that about 55% of these patients worried about the onset of their next exacerbation and that they spent on average over a third of the year (136 days) with their eczema in flare.2

Link Between Depression, Suicidal Thoughts and Later Parental-Mandated Bedtimes For Teens
Earlier parental-mandated bedtimes could help protect teens from depression and suicidal thoughts by lengthening sleep duration, according to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
News of the day
New Treatment Option At The Sarah Cannon Cancer Center Provides Hope For Inoperable Tumors
The Sarah Cannon Cancer Center (SCCC) at Centennial Medical Center last week began treating patients with a new non-invasive weapon in the battle against cancer. The Sarah Cannon Cancer Center is the first and only cancer center in Middle Tennessee to offer image-guided robotic stereotactic radiosurgery.
Endocrinology

International Team Tracks Clues To HIV

Rice University"s Andrew Barron and his group, working with labs in Italy, Germany and Greece, have identified specific molecules that could block the means by which the deadly virus spreads by taking away its ability to bind with other proteins. Using computer simulations, researchers tested more than 100 carbon fullerene, or C-60, derivatives initially developed at Rice for other purposes to see if they could be used to inhibit a strain of the virus, HIV-1 PR, by attaching themselves to its binding pocket. "There are a lot of people doing this kind of research, but it tends to be one group or one pharmaceutical company taking a shotgun approach -- make a molecule and try it out, then make another molecule and try it out," said Barron, Rice"s Charles W. Duncan Jr.-Welch Professor of Chemistry and professor of materials science. "This is interesting because we"re tackling an important problem in a very rational way." The groups reported their findings in a paper published on the American Chemical Society"s Journal of Chemical Information and Modeling Web site last week. Their method of modeling ways to attack HIV may not be unique, but their collaboration is. Research groups from five institutions -- two in Greece, one in Germany, one in Italy and Barron"s group at Rice -- came together through e-mail contacts and conversations over many months, each working on facets of the problem. "Not all the groups have ever met in person," Barron said. Most remarkable, he said, is that their research to date has been completely unfunded. Using simulations to narrow down a collection of fullerenes to find the good ones is "the least time-consuming low-cost procedure for efficient, rational drug design," the team wrote. "A long time ago, people noticed that C-60 fits perfectly into the hydrophobic pocket in HIV, and it has an inhibition effect," Barron said. "It"s not particularly strong, but there"s potentially a very strong binding effect. The problem is, it"s not the perfect unit." The objective was to find an existing fullerene derivative molecule that could be easily modified to become the perfect unit. Rice got involved, he said, "because we make the molecules and the other guys had a great method for in-silico testing of molecules. They approached us and said, "Do you think we could use some of these?" Then we started bouncing ideas around. "We began thinking about a very simple experiment to calculate the binding efficiency of a molecule in the HIV pocket, then calculate that for a series of molecules, decide which one is best, make that molecule in real life and see if it correlates," Barron said. "If it does, then you"ve got a way to design your ultimate molecule. Our work was the first step in the process." In fact, through their "in-silico," or computer-based, calculations, they found two good fits among the fullerene derivatives tested and are now working to enhance their binding properties to get that perfect molecule, one that sticks "like Velcro" to the virus and can be fine-tuned for various strains. "This is just one component of the problem -- we"re not going to cure HIV," Barron cautioned. The hope, he said, is to develop a method for the rapid creation of drugs to address various strains of HIV and other diseases. Authors of the paper with Barron were Manthos Papadopoulos of the National Hellenic Research Foundation, Athens; Serdar Durdagi of the National Hellenic Research Foundation and the Freie Universitat, Berlin; Claudiu Supuran of the University of Florence, Italy; T. Amanda Strom, Nadjmeh Doostdar and Mananjali Kumar of Rice; and Thomas Mavromoustakos of the National Hellenic Research Foundation and the University of Athens. The impromptu nature of the project intrigued Barron as much as the subject itself. "Here you"ve got computational people, experimental people, synthesis people, characterization people who"ve come together naturally as a collaboration and developed this protocol, developed their own methodologies. "And no one"s paid us to collaborate. Serdar Durdagi"s graduate fellowship was funded by the European Union. The fellowships of Rice graduate students Amanda Strom, Nadjmeh Doostdar and Mananjali Kumar were funded, in part, by Rice"s Center for Biological and Environmental Nanotechnology. This is purely an academic collaboration." He said the group is working on a second paper and seeking funding to expand the project. David Ruth Rice University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):